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Background: The study investigated the use of combined photodynamic therapy (PDT) and 
stent placement for the treatment of cholangiocarcinoma (CC). For this purpose, 5-aminolevulinic 
acid (ALA) was incorporated into poly(vinyl alcohol) (PVA) nanofiber, and coated onto metal 
stents. Their efficacy was assessed in PDT towards HuCC-T1 CC cells.
Methods: Fabrication of ALA-PVA nanofiber, and simultaneous coating onto metal stents, 
was performed through electrospinning. The dark-toxicity, generation of protoporphyrin IX 
(PpIX), and PDT effect of ALA and ALA-PVA nanofiber were studied in vitro, using HuCC-T1 
CC cells.
Results: The ALA-PVA nanofibers were coated onto metal stents less than 1000 nm in diameter. 
ALA-only displayed marginal cytotoxicity; ALA-PVA nanofiber showed less cytotoxicity. PpIX 
generation was not sigficantly different between ALA and ALA-PVA nanofiber treatments. PVA 
itself did not generate PpIX in tumor cells. ALA and ALA-PVA nanofiber displayed a similar 
PDT effect on tumor cells. Cell viability was decreased, dose-dependently, until ALA concen-
tration reached 100 µg/mL. Necrosis and apoptosis of tumor cells occurred similarly for ALA 
and ALA- PVA nanofiber treatments.
Conclusion: The ALA-PVA nanofiber-coated stent is a promising candidate for therapeutic 
use with cholangiocarcinoma.
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Introduction
Cholangiocarcinoma (CC) is a malignant tumor that arises from epitheial cells 
of the biliary tree.1 Prognosis for CC is generally poor, with a 5-year survival 
rate of less than 5%.2 In the absence of curative treatment, the median survival of 
advanced CC patients is less than 24 months.2–4 Surgical removal of advanced stage 
CC is practically impossible. Palliative therapies, such as endoscopic stent placement, 
chemotherapy, radiation therapy, and photodynamic therapy (PDT) have been assessed 
as methods for prolonging survival.5–7
PDT incorporates a photosensitizer, light source, and oxygen. Individually, the 
components are nontoxic. The activated (irradiated) form of the photosensitizer is 
toxic at the site of action.8,9 Among various photosensitizers, 5-aminolevulinic acid 
(ALA), is a precursor of a strong photosensitizing agent, protoporphyrin IX (PpIX). 
ALA has been used extensively in clinical applications, due to its safety, feasibility 
as an effective endogenous photosensitizer for fluorescence diagnosis, and its efficacy 
in PDT.9–12 Photosensitizing agents, administered systemically or locally, accumulate 
mainly in tumor cells. The agent is activated, using light of a specific wavelength, to 
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induce a photochemical inhibitory effect upon cancer cells 
that contain the activated compound.
Nanoscale materials and devices, such as nanoparticles, 
nanofibers, and nanodevices represent a new class of 
biomedical materials, which have unique biochemical and 
physiological properties.13–16 Polymer nanofibers, espe-
cially, have been investigated extensively for biomedical 
applications in recent decades.15,17,18 Because they are of 
similar scale to biological structures and systems, nanofibers 
are able to mimic the biological microenvironment and 
stimulate the therapeutic potential of medical agents.
In this study, we explored the novel concept of combin-
ing metal stent placement and ALA-based PDT as a therapy 
for CC. ALA was incorporated into poly(vinyl alcohol) 
(PVA) nanofibers (ALA-PVA) and coated onto metal stents. 
In this preliminary study, the PDT effect of this nanofiber 
was investigated in vitro using CC cells.
Methods and materials
Materials
PVA (13,000–23,000 g/M; 87%–89% hydrolyzed), ALA, 
2′,3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT), and 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES) were purchased from Sigma-Aldrich 
(St Louis, MO). Cell culture materials were purchased 
from Invitrogen (Carlsbad, CA). Propidium iodide (PI) and 
fluorescein isthiocynate (FITC)-annexin V were obtained 
from BD Biosciences (Sparks, MD).
Metal stent coated with PVA nanofiber
To prepare the nanofiber-coated stents, 1350 mg of PVA and 
150 mg of ALA were completely dissolved in 10 mL of water. 
This solution was transferred into a spin pack containing 
  spinnerets. Electrospinning was carried out using typical 
  apparatus (Amotech, Kimpo, Korea). A voltage of 25 kV was 
applied to the polymer solution via the spinneret tip (Figure 1A).19 
PVA solutions containing ALA were sprayed onto a rolling 
collector (diameter: 1 cm; length:10 cm; rolling speed: 800 rpm) 
at a rate of 50 µL per minute. PVA nanofiber-coated stents 
were dried for 3 hours in darkness, with reduced pressure. The 
nanofiber-coated stents were then carefully isolated from the 
collector and weighed. For studying PDT, ALA- PVA nanofiber 
was suspended in phosphate-buffered saline (PBS) (0.01 M, 
pH 7.4), then sterilized using a 0.2 µm syringe filter.
Cell culture
The HuCC-T1 human intrahepatic CC cell line was obtained 
from Health Science Research Resources Bank (Osaka, 
Japan). The cells were cultured in RPMI1640, containg 10% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin, 
buffered with 25 mM HEPES in an incubator operated at at 
37°C with 5% CO2 concentration.
PpIX accumulation assay
HuCC-T1 cells (1 × 106) were seeded in 6-well plates and 
treated with ALA for 24 hours in serum-free medium, 
washed with PBS, then lysed with cell lysis buffer 
(GenDEPOT, Barker, TX). PpIX accumulation in cells 
was measured using an Infinite® M200 PRO microplate 
reader (Tecan, Männedorf, Switzerland), at excitation 
and emission wavelengths of 485 nm and 635 nm, 
respectively.
Dark toxicity
HuCC-T1 cells were seeded in wells of a 96-well plate 
(1 × 104 cells/well) with 100 µL of culture medium. Cells 
were incubated in a CO2 incubator at 37°C for 24 hours. 
Cells were then treated with various concentrations of ALA, 
or ALA-PVA nanofiber, in serum-free medium for 24 hours. 
The medium was changed to a growth medium, containing 
10% FBS, and incubated for 24 hours. Cell viability was 
measured by MTT assay, as reported previously.20 25 µL of 
MTT (3 mg/mL in PBS) was added to each well, and cells 
were then incubated for an additional 4 hours. Subsequently, 
100 µL of sodium dodecyl sulfate (10% w/v)- hydrochloric 
acid (0.01 M) solution was added to each well, and cells 
were incubated for an additional 12 hours at 37°C with 5% 
CO2. Next, absorbance was measured at a wavelength of 
570 nm using the Infinite® M200 PRO reader. All experiments 
were conducted in triplicate. Cell viability was expressed 
in percentages against controls. Results were calculated 
as means with standard deviations for three different 
experiments.
Light sources for PDT
Cultured cell plates were exposed to light-emitting diode 
irradiation lamps (SH System, Gwangju, Korea), at 635 nm 
wavelength. Light intensity was 0.25 J/cm2, as measured by 
a photo radiometer (Delta Ohm, Padua, Italy).
Cell viability assay
HuCC-T1 cells were treated with various concentrations 
of ALA or ALA-PVA nanofiber in serum-free medium for 
24 hours. Cells were then irradiated with 0.25 J/cm2 at 635 nm 
wavelength. The medium was changed, and cell viability 
was assessed by MTT assay.
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Flow cytometry
Apoptosis and necrosis of HuCC-T1 cells were analyzed by 
flow cytomwtry.7 FITC annexin V and PI were employed 
to analyze apoptosis and necrosis of HuCC-T1 cells, 
respectively. Cells were exposed to ALA for 24 hours, then 
irradiated with 0.25 J/cm2 at 635 nm wavelength. Cells were 
harvested and washed with PBS. Cell pellets were then 
resuspended in a binding buffer (pH 7.4; 10 mM HEPES, 
150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2), 
containing FITC annexin V (1 µg/mL), then further incubated 
for 30 minutes. Ten minutes prior to the termination of 
incubation, PI (10 µg/mL) was added, to stain necrotic cells 
under dark conditions. Cells were analyzed immediately, 
using a FACScan™ flow cytometer (Becton Dickinson 
Biosciences, San Jose, CA).
Fluorescence microscopy
Accumulation of PpIX was observed using an Eclipse 80i 
fluorescence microscope (Nikon, Tokyo, Japan). PpIX was 
detected using a 460–480 nm excitation filter and 610 nm 
A
ALA + PVA solution
Metal stent
B
WD20.9 mm SE
10 µm
10 µm x3.ok
Figure 1 (A) Schematic illustration of ALA-PVA nanofiber coated onto metal stent; (B) field emission-scanning electron microscopy image.
Abbreviations: ALA, 5-aminolevulinic acid; PVA, poly(vinyl alcohol).
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emission filter. Cells were seeded onto cover glasses, 
positioned in a 6-well plate (1 × 106 HuCC-T1 cells/well), 
then treated with ALA or ALA-PVA nanofiber for 24 hours 
in serum-free medium. The medium was discarded, and 
the cover glasses were washed with PBS. The cells were 
fixed for 10 minutes in 4% paraformaldehyde in PBS, and 
mounted onto glass slides. PpIX generation in tumor cells 
was observed with fluorescence microscopy.
Results
Characterization of ALA-incorporated 
PVA nanofibers
The porous and fibrous nanomaterial, PVA-ALA, was coated 
onto metal stents (Figure 1). PVA-ALA nanofibers were 
properly coated onto the stents (Figure 1B). The diameter 
of the coated fibrous matter varied, but was always less than 
1000 nm. To test its biological activity and phototoxicity, 
ALA-PVA nanofiber was suspended in PBS.
Dark toxicity
Before investigating the effect of ALA-PVA nanofiber with 
PDT, we studied the intrinsic toxicities of ALA and ALA-
PVA, using HuCC-T1 cells. As shown in Figure 2, vari-
ous concentrations of ALA and ALA-PVA (drug/polymer 
ratio: 1/9) were used to treat HuCC-T1 cells for 24 hours, in 
the absence of irradiation. ALA itself was only marginally 
toxic; survival exceeded 70%, even at ALA concentrations 
less than 100 µg/mL; ALA-PVA was even less cytotoxic. 
Interestingly, PVA appeared to reduce the intrinsic toxicity 
of ALA. 90% survival of tumor cells was noted in ALA con-
centrations that exceeded 200 µg/mL. These results indicate 
that PVA, and PVA nanofibers, did not appreciably affect the 
viability of HuCC-T1 cells.
PpIX generation in HuCC-T1 cells  
and phototoxicity
PpIX generation in HuCC-T1 CC cells treated with ALA or 
ALA-PVA nanofiber is summarized in Figure 3. The extent 
of PpIX generation was not significantly different between 
ALA-only and ALA-PVA nanofiber treatment. PVA itself 
did not generate PpIX in tumor cells. Interestingly, at ALA 
concentrations greater than 50 µg/mL, PpIX generation, 
under treatment with ALA-PVA nanofiber, was slightly 
greater than for ALA only. PpIX generation in HuCC-T1 cells 
was confimed by fluorescence microscopy (Figure 4), which 
indicated that ALA-PVA nanofiber produced PpIX in tumor 
cells as avidly as did ALA alone. Figure 5 summarizes data 
concerning the phototoxicity of ALA and ALA-PVA nano-
fiber towards HuCC-T1 cells. Tumor cells were irradiated 
24 hours after treatment with ALA or ALA-PVA nanofiber. 
120.0 ALA only 
ALA-PVA nanofiber 
100.0
80.0
60.0
40.0
20.0
0.0
0 0.01 0.1 1 5 10
ALA concentration (µg/mL)
% of control
25 50 100 150 200
Figure 2 Dark toxicity of ALA-only and ALA-PVA nanofiber against HuCC-T1 cholangiocarcinoma cells.
Notes: ALA, dissolved in dimethylsulfoxide, was diluted with serum-free media at least 100 times, then used in treating HuCC-T1 cells. For ALA-PVA, a calculated amount 
of nanofiber (ALA/PVA ratio: 1/9, w/w), from metal stents suspended in serum-free medium, was sterilized using a syringe filter (pore size: 0.2 µm). The preparation was 
used to treat tumor cells.
Abbreviations: ALA, 5-aminolevulinic acid; PVA, poly(vinyl alcohol).
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Figure 4 Fluorescence images of HuCC-T1 cholangiocarcinoma cells after treatment with ALA and ALA-PVA nanofiber.
Notes: (A) zero ALA; (B) 10 µg/mL ALA; (C) 10 µg/mL ALA-PVA nanofiber; (D) 25 µg/mL ALA; (E) 25 µg/mL ALA-PVA nanofiber; (F) 100 µg/mL ALA; (G) 100 µg/mL 
ALA-PVA nanofiber.
Abbreviations: ALA, 5-aminolevulinic acid; PpIX, protoporphyrin IX; PVA, poly(vinyl alcohol).
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Figure  3  The  effect  of  ALA  and  ALA-PVA  nanofiber  on  PpIX  generation  in 
HuCC-T1 CC cells.
Notes: ALA dissolved in dimethylsulfoxide was diluted with serum-free media at 
least 100 times, then used in treating HuCC-T1 cells. For ALA-PVA, the procedure 
detailed in the notes to Figure 2 was followed.
Abbreviations:  ALA,  5-aminolevulinic  acid;  CC,  cholangiocarcinoma;  PpIX, 
protoporphyrin IX; PVA, poly(vinyl alcohol).
The decrease in cell viability caused by ALA-PVA nanofiber 
treatment was very similar to that caused by ALA alone, 
whereas PVA alone did not induce death in tumor cells 
(Figure 5). Tumor cell viability decreased dose-dependently 
until ALA concentration reached 100 µg/mL, and remained 
constant with increased concentration. These results indicate 
that PpIX was generated in a dose-dependent manner by 
treatment with ALA or ALA-PVA nanofiber, which induced 
PDT-mediated cell death.
Apoptosis and necrosis of tumor cells
To investigate the mechanism of tumor cell death, HuCC-T1 
cells, treated with ALA or ALA-PVA nanofiber, were stained 
with FITC annexin V , to detect apoptotic cells, and with PI, 
to detect necrotic cells. As shown in Figure 6, the number of 
necrotic and apoptotic cells gradually increased until an ALA 
concentration of 25 µg/mL was reached. At 100 µg/mL ALA, 
the number of necrotic cells significantly increased, while 
that of apoptotic cells slightly decreased, indicating that these 
results are a reflection of cell death. Necrosis of tumor cells 
was dominant at ALA concentrations exceeding 100 µg/mL.
Discussion
CC is an incurable adenocarcinoma, arising from cholangio-
cytes. Even though operative removal would offer the greatest 
hope for a cure, this option is impossible. Palliative therapeutic 
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modalities are generally used, such as radiotherapy, chemo-
therapy, stent placement, and PDT. Among these modalities, 
no beneficial effect can be expected from radiotherapy or 
chemotherapy.6,21–23 PDT and metal stent placement are the 
most promising approaches for prolonging patient life.24,25 
When a tumor blocks the bile duct, insertion of a metal 
stent enables bile drainage. An uncoated metal stent offers 
simple mechanical palliation, without anti-tumor efficacy.26 
In a recent review, Chahal and Baron25 suggested that PDT 
with stenting could hold promise for managing locally unre-
sectable cholangiocarcinoma, rather than solely as a means 
for prolongation of life. The advantages of PDT include its 
safety; minimal side-effects compared to radiotherapy or 
chemotherapy; and the feasibility of local treatment for gas-
trointestinal cancer, because nontoxic components – light and 
a photosensitizing agent – are used for treatment.25,27
Nanofiber  technology,  for  drug  delivery  or 
biotechnological applications, has been investigated 
extensively over recent decades.15–17 Nanofibers form an 
ultraporous matrix with superior mechanical properties and 
high surface area for weight.28,29 Various types of polymeric 
materials can be used to make them.28,29 Nanofibers fabricated 
with PVA and poly(N-isopropylacrylamide) are known 
to be effective vehicles for enhanced topical delivery of 
drugs.30 The nanofibrous membrane of PVA has previously 
been used to maintain the stability and biological activity 
of (-)-epigallocatechin-3-gallate (EGCG).31 The cellular 
response of PVA nanofibers containing silver nanoparticles 
has also been investigated.32
We prepared ALA-PVA nanofiber-coated metal 
stents using the electrospinning method (Figure 1). 
PVA, which is a water-soluble surfactant, can be used as 
a vehicle for ALA, because ALA is a small, water-soluble 
molecule, insoluble in organic solvents. Since ALA is labile 
and light sensitive, PVA nanofiber could help to maintain its 
stability and biological activity.
ALA-PVA nanofiber was coated onto the metal stent – not 
uniformly. PVA nanofiber itself did not affect the viability of 
tumor cells (Figure 2). Since PpIX generation was slightly 
increased at high ALA concentration (Figures 3 and 4), 
ALA-PVA nanofiber coating of metal stents is a promising 
method for delivery of ALA to tumor cells. We previously 
reported that nonionic surfactants, such as Pluronic® F68 or 
Tween® 80 (Sigma-Aldrich), effectively enhance ALA uptake 
by tumor cells.33 We suggest that PVA nanofibers are also 
effective vehicles for delivery of ALA.
The present study combined PDT with stent placement, 
for palliative therapy for CC (Figure 7). Cheon et al reported 
that PDT with stenting resulted in longer survival than stenting 
alone.34 They observed longer survivability in patients after 
PDT treatment and subsequent placement of a metal stent. 
Local administration of a photosensitizer, combined with a 
metal stent, can be considered a more feasible treatment option 
than that of systemic administration, in the case of bile duct 
cancer, because local treatment provides better accumulation 
and more favorable biodistribution of photosensitizer in tumor 
tissue, leading to selective tumor cell death.35 We prepared 
ALA-PVA nanofiber to coat metal stents (Figure 1). As far as 
we know, this is the first use of this suggestion for palliative 
therapy for unresectable CC; it was suggested that PDT and 
stent placement offer hope for such treatment.22–26 As shown 
in Figure 7, combined   treatment, with PDT and ALA-PVA 
nanofiber-coated metal stent, involved only two steps. In the 
first step, the nanofiber-coated stent is placed in the bile duct 
compromised by CC. At this stage, PpIX is generated after 
uptake of ALA by tumor cells. In the second step, irradia-
tion is perfomed. PDT inhibits the growth or spread of the 
tumor. For this purpose, we selected ALA as a photosensi-
tizing agent, because ALA is less cytotoxic towards normal 
cells in the absence of irradiation, compared with other 
photosensiting agents.   Furthermore, PpIX accumulation in 
ALA-treated tumor cells is greater than in normal cells.7 In 
general, the method for PDT treatment is a two-step process, 
involving (1) accumulation of the photosensitizing agent in 
tumor cells, and (2) subsequent lethal activation of the agent 
by irradiation at a specific wavelength.7 Irradiation induces 
an injurious photochemical reaction, in which the activated 
agent transfers energy to molecular oxygen, generating 
reactive oxygen species,7 which oxidize lipids, amino acids, 
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Figure 5 Phototoxicity of ALA and ALA-PVA nanofiber towards HuCC-T1 CC cells.
Notes: HuCC-T1 cells were treated with ALA or ALA-PVA nanofiber in serum-
free medium for 24 hours. Cells were then irradiated with 0.25 J/cm2 at 635 nm 
wavelength.
Abbreviations: ALA, 5-aminolevulinic acid; CC, cholangiocarcinoma; PVA, poly(vinyl 
alcohol).
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Figure 7 schematic illustration of combination of stent placement and PDT for cholangiocarcinoma.
Abbreviations: PDT, photodynamic therapy; ALA, 5-aminolevulinic acid; PVA, poly(vinyl alcohol).
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and proteins, inducing necrosis and apoptosis. As shown 
in Figure 5, ALA-PVA nanofiber maintained a PDT effect 
similar to that of ALA alone. In the absence of irradiation, 
reduced cytotoxicity was observed with ALA-PVA nanofiber 
(Figure 2). PpIX generation increased with greater ALA 
c  oncentration. PVA itself did not influence the interconversion 
between ALA and PpIX (Figures 3 and 4). Even though the 
extent of apoptosis and necrosis changed slightly, ALA-PVA 
nanofiber treatment showed a similar cell death mechanism to 
ALA alone, in the apoptosis and necrosis analyses (Figure 6). 
Necrosis predominated at ALA concentrations greater than 
100 µg/mL. Apoptosis resulting from treatment with ALA-
PVA nanofiber was slightly greater than that resulting from 
ALA alone. These results indicate that that ALA-PVA nano-
fiber has anti-tumor activity, and can generate a PDT effect 
on HuCC-T1 CC cells.
Conclusion
ALA-PVA nanofiber was coated onto metal stents for 
combined PDT and stent placement for palliative therapy of 
unresectable CC. ALA-PVA nanofiber maintained activity 
similar to ALA alone in generation of PpIX, contributing 
to cell death, while it was less cytotoxic in the absence of 
irradiation. ALA-PVA nanofiber-coated stents offer promise 
in therapy for CC.
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